Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
0 hedge funds and large institutions have $0 invested in Evofem Biosciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 8 closing their positions.
100% less funds holding
Funds holding: 8 → 0 (-8)
100% less capital invested
Capital invested by funds: $9.12K → $0 (-$9.12K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$5K |
| 2 |
AWM
Activest Wealth Management
Aventure,
Florida
|
-$2K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$2K |
| 4 |
WIM
Westside Investment Management
Santa Monica,
California
|
-$113 |
| 5 |
LTI
Laffer Tengler Investments
Nashville,
Tennessee
|
-$2 |
EVFM Hedge Fund Activity: Q4 2022 in Review
0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2022, worth a combined $0 — down 100% from $9.12K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of EVFM and 0 opened new positions — a net loss of 8 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Clear Street, exiting entirely with an estimated $5K sold.
- 0 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2022, down from 8 in Q3 2022.
- Funds reported $0 of Evofem Biosciences, Inc. Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2022 and 8 closed out, a net change of -8 holders.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2022 was Clear Street, an estimated $5K sold.
Based on aggregated 13F filings for Q4 2022.